Why the study?
The 2022 AHA/ACC/HFSA guideline recommended SGLT2 inhibitors for patients with heart failure and type 2 diabetes based on trials excluding recent studies in HFpEF.
Endorses SGLT2 inhibitor use to cut HF morbidity in T2D; extends benefits to HFpEF.
2022 AHA/ACC/HFSA guideline for the management of heart failure, which is valuable for clinical decision-making, was recently released. This guideline recommended patients with heart failure with type 2 diabetes sodium‑glucose co-transporter‑2 inhibitors for the management of hyperglycemia and to reduce heart failure-related morbidity and mortality (Class 1, Level A). It is important to note that the source of evidence based on this recommendation is from EMPEROR-Reduced, DAPA-HF, and DECLARE-TIMI 58 and does not include newly published PRESERVED-HF, CHIEF-HF, and EMPEROR-Preserved. Here we reviewed these important trials in order to provide more clinical references for patients with diabetes and heart failure, especially heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2022) conducted a review in Diabetes with heart failure. Sodium-glucose co-transporter-2 inhibitors was evaluated. Sodium-glucose co-transporter-2 inhibitors are recommended by the 2022 AHA/ACC/HFSA guidelines to manage hyperglycemia and reduce morbidity and mortality in patients with heart failure and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: